Wells Fargo analyst Yanan Zhu raised the firm’s price target on Crispr Therapeutics (CRSP) to $75 from $65 and keeps an Equal Weight rating on the shares. Initial preclinical data for the SyNTase prgm in AATD are encouraging, and there’s potential for broader applications, the firm says.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics AG: Promising Advancements in Gene Editing and Strategic Market Entry Justify Buy Rating
- Crispr Therapeutics AG: Buy Rating Backed by Innovative SyNTase Platform and Promising Preclinical Data
- Crispr Therapeutics AG: Promising Advancements in Gene Editing Justify Buy Rating
- Crispr presents new preclinical data from SyNTase gene editing platform
- Crispr Therapeutics to present preclinical data on AATD at ESGCT 2025